It should be pointed out that the current ATR inhibitors used in cancer clinical trials are specific inhibitors of ATR kinase activity which is pivotal to the hallmark ATR’s DNA damage checkpoint functions in the nucleus. This evidence concerns the gene ATR and cancer.